SCHEMBL799148

SCHEMBL799148

Cc1cc(Cl)nc(N2CCc3nc(NC(=O)Nc4ccccc4C(=O)NC(C)C)sc3C2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.43
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
P2RY1 P47900 2/20 0.41
PIK3CG P48736 6/20 0.41
HCAR1 Q9BXC0 1/20 0.39
GCK P35557 1/20 0.39
ALDH1A1 P00352 1/20 0.39
POLB P06746 1/20 0.39
PIK3CD O00329 1/20 0.39
ROCK2 O75116 1/20 0.39
F10 P00742 1/20 0.39
GAA P10253 1/20 0.39
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
HPGD P15428 1/20 0.38
CYP2C19 P33261 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL799149 0.88 LMNA (0.43) LMNAMEN1KMT2AP2RY1PIK3CG
SCHEMBL799264 0.85 PIK3CG (0.43) LMNAMEN1KMT2AP2RY1PIK3CG
SCHEMBL172152 0.84 LMNA (0.43) LMNAMEN1KMT2AP2RY1PIK3CG
SCHEMBL799343 0.83 LMNA (0.42) LMNAMEN1KMT2APIK3CGGCK
SCHEMBL172045 0.82 PIK3CG (0.54) LMNAMEN1KMT2APIK3CGGCK
SCHEMBL798936 0.82 LMNA (0.44) LMNAMEN1KMT2AP2RY1PIK3CG
SCHEMBL799269 0.82 PIK3CG (0.51) LMNAMEN1KMT2APIK3CGALDH1A1
SCHEMBL799274 0.81 PIK3CG (0.53) LMNAMEN1KMT2APIK3CGALDH1A1
SCHEMBL805072 0.81 LMNA (0.44) LMNAMEN1KMT2AP2RY1PIK3CG
SCHEMBL798946 0.80 P2RY1 (0.40) LMNAMEN1KMT2AP2RY1PIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120071475-A1 UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2012-03-22 US disclosed
US-20120071475-A1 UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071475-A1 UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY MTOR, STAT3, SLC14A1 LMNA 4258/4885MEN1 2694/4885KMT2A 2921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.